Nav: Home

Blocking the migration of cancer cells to destroy them

August 04, 2016

Lymphoma is a cancer that affects lymphocytes, a type of white blood cell. The disease originates in a lymphoid organ (lymph node, spleen, or bone marrow) before spreading through the blood to infiltrate not only other lymphoid organs but also other tissues. Every year, nearly 2,000 people in Switzerland are diagnosed with lymphoma, a disease that can be very aggressive, resisting standard treatments with chemotherapeutic drugs. Today, researchers at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG), Switerland, give a new hope to patients. Their innovative approach consists in using an antibody able to neutralize a specific protein to block the migration of lymphoma cells, thus preventing the disease from developing. This still experimental immunotherapeutic strategy paves the way for new treatments against lymphoma. The results can be read in the Journal of Leukocyte Biology.

Lymphocytes, a special type of white blood cell, are essential components of the immune system. But like any other cell, they are not safe from carcinogenic mutations that can cause uncontrolled proliferation. They can then circulate freely in the blood and spread to the lymphatic system, thus causing a tumor called lymphoma.

Lymphoma cells only become truly dangerous when they leave the blood vessels and multiply in the lymphatic system. 'Since they cannot survive in the blood for long, these malignant cells are compelled to find a more accommodating environment - such as the lymphatic system - where they can proliferate. We decided to focus on this Achilles heel by containing them in the blood so as to prevent any resulting harm', explains Thomas Matthes, Professor at UNIGE, Faculty of Medicine, and Doctor at HUG, who supervised the study together with Beat Imhof, Professor at UNIGE, Faculty of Medicine.

A way to prevent malignant cell circulation

The inner wall of blood vessels is formed by a layer of endothelial cells that act as a barrier, which prevents the blood cells from leaving the circulation. Yet, some lymphocytes, having mutated to become cancerous, are equipped with a specific surface marker, the JAM-C protein, also present on the surface of endothelial cells. Like a free pass, its presence on the surface of lymphoma cells facilitates their migration through the vessel walls between adjacent endothelial cells. In order to block the effect of this protein, the scientists drew upon the immune system to develop an antibody targeting JAM-C. Named 'H225' this molecule was designed to bind solely to JAM-C. What was the effect on the lymphoma cells? By masking JAM-C, H225 was able to prevent the cells from migrating out of the blood vessels.

A two-faceted antibody

The H225 antibody proved itself very efficient, decreasing the transit of cancerous cells into the organs of the lymphatic system by over 50%. 'This is not its only effect, Thomas Matthes adds, H225 also significantly limited cell proliferation, even when tumor cells had already settled in the lymphatic system. In our mice, we observed the nearly-complete disappearance of already-present tumor cells in the organs.'

This discovery is in line with the recent advances in cancer immunotherapy, a field that focuses on the design of treatments based on the human immune system. With their specific interest in the JAM-C marker, the Geneva team has laid the foundation for a new therapeutic strategy against lymphoma. The researchers now focus their ongoing efforts on the quest for an efficient treatment that could, in the near future, be offered to patients.
-end-


Université de Genève

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...